The clearest sign that metformin is working is a measurable drop in your A1C and fasting blood glucose over 3 months — typically 0.5 to 1.5 percentage points off A1C and 20 to 50 mg/dL off fasting glucose at full dose. Because metformin acts subtly on hepatic glucose output and insulin sensitivity, most people do not “feel” it working. The lab numbers tell the real story.
The Primary Sign: A1C Drop at 3 Months
Metformin’s defining outcome is a reduction in hemoglobin A1C, the 90-day average glucose marker. According to the American Diabetes Association (ADA) Standards of Care, metformin monotherapy lowers A1C by approximately 1 to 2 percentage points in patients with type 2 diabetes when used at therapeutic doses (1,500 to 2,000 mg per day). For people with prediabetes in the Diabetes Prevention Program (DPP), metformin reduced progression to type 2 diabetes by 31 percent over an average follow-up of 2.8 years. Your prescriber will typically order an A1C test at the 3-month mark after starting or changing your metformin dose, since that is when the full effect on the 90-day average becomes visible. For background on what A1C means, see our A1C levels guide.
Fasting Glucose: The Earlier Signal
Fasting glucose responds before A1C does. Metformin’s primary mechanism is suppression of hepatic gluconeogenesis — the liver’s overnight production of glucose — so fasting morning readings tend to drop within 1 to 2 weeks of reaching a stable dose. If you are using a home glucose meter or continuous glucose monitor (CGM), watch the fasting trend over a 2-week window. Erratic single readings are less informative than a downward shift in the 14-day average.
| Marker | Expected Change | Time to See It |
|---|---|---|
| Fasting glucose | Down 20-50 mg/dL | 1-2 weeks at stable dose |
| Post-meal glucose | Less peak above 180 mg/dL | 2-4 weeks |
| A1C | Down 0.5-1.5 percentage points | 3 months |
| Weight | Loss of 2-6 lb in some patients | 3-6 months |
| Fatigue and energy | Subjective improvement | 4-8 weeks |
Fewer Post-Meal Spikes
If you wear a CGM or test 2 hours after meals, you may notice that post-meal peaks are less dramatic and return to baseline faster within the first month. Metformin modestly improves insulin sensitivity in muscle and adipose tissue, which helps clear glucose after carbohydrate-containing meals. The effect is smaller than what GLP-1 agonists or SGLT2 inhibitors produce on postprandial glucose, but it is real and measurable in many patients.
Slow, Modest Weight Loss in Some Patients
Metformin is weight-neutral to mildly weight-reducing. Average loss in clinical trials is 2 to 6 pounds over 6 months, primarily through reduced appetite and a modest GLP-1-like effect on the gut. This is much less than what GLP-1 agonists produce, but the absence of weight gain — which is common with sulfonylureas and insulin — is a meaningful side benefit. If you are losing several pounds in the first 2 to 3 months without trying, that is a reasonable indirect sign metformin is working.
What Metformin Does Not Cause You to Feel
Unlike insulin or sulfonylureas, metformin does not cause hypoglycemia in most patients. There is no abrupt rush of energy or sudden hunger that signals it is “kicking in.” Many newly treated patients ask their prescriber whether the medication is working because they feel exactly the same as before. That is normal and expected. The drug operates in the background, lowering hepatic glucose production and improving cellular insulin response. The only way to confirm it is working is through lab testing.
Side Effects Are Not the Same as Effectiveness
Many patients assume that gastrointestinal side effects (nausea, diarrhea, metallic taste) mean the drug is “doing its job.” The two are unrelated. GI side effects come from metformin’s local action on the small intestine; glucose-lowering comes from systemic absorption and action on the liver and muscle. You can have a robust glucose-lowering response with no GI symptoms, or significant GI symptoms with only modest glucose effect. The extended-release (ER) formulation reduces GI side effects by about 50 percent without sacrificing efficacy.
The Realistic Timeline
The standard titration is to start at 500 mg once or twice daily with food and increase weekly to a target of 1,500 to 2,000 mg per day. According to the Glucophage prescribing information, the maximum recommended dose is 2,550 mg per day for IR and 2,000 mg per day for ER. Full glucose-lowering effect at the target dose develops over 4 to 6 weeks. The A1C re-check at 3 months is the formal moment of truth. If you are still 0.5 to 1.0 percentage points above target, your clinician will discuss either pushing the dose higher or adding a second agent.
When to Worry About Lack of Response
If your A1C has not dropped by at least 0.3 to 0.5 percentage points at 3 months on a therapeutic dose, talk to your prescriber. Reasons for poor response include suboptimal dose, inconsistent adherence, advanced beta-cell loss in long-standing diabetes, untreated thyroid disease, recent steroid use, weight gain, and rare cases of metformin transporter genetic variants that reduce drug uptake. Combination therapy with a GLP-1 agonist or SGLT2 inhibitor is now first-line in many guidelines for patients with cardiovascular or kidney disease, and your clinician may recommend that path. Our treatment hub covers other options. For people whose prediabetes is the focus, the prediabetes reversal guide reviews lifestyle synergies.
The Bottom Line
Metformin works in the background, and the proof is in the lab. The clearest signs that it is working are a measurable drop in fasting glucose within 1 to 2 weeks and a 0.5 to 1.5 point decline in A1C at the 3-month re-check. Side effects are not a marker of effectiveness. If you reach 3 months at full dose without a meaningful drop, talk to your prescriber about next steps rather than assuming the drug failed.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan.
